Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Modulight Corporation | Press Release | February 14, 2024 at 12:05:00 EET
Modulight is pleased to announce its participation in the GlioLighT project, aimed at developing new treatment options for gliomas. This project has received substantial funding of approximately EUR 2.2 million over three years from the European Innovation Council's Pathfinder program. The GlioLighT project partners include Johannes Gutenberg University Mainz, Aston University in Birmingham, the University of Barcelona, LMU Munich, and MODUS Research and Innovation Ltd. The budgetary allotment of the project for Modulight is about EUR 400,000 over the duration of the project.
Gliomas, known for their complexity and difficulty to treat, have long posed a significant challenge in neuro-oncology. Modulight has been active in glioma therapies since the launching of their clinical multi-drug light delivery platform ML7710 in 2014 and working on photoimmunotherapy clinical studies since 2015. This project builds on the Modulight’s unique, multi-indication cloud-connected ML7710 product platform.
The GlioLighT project uses a direct light therapy approach for gliomas. This method involves the generation of reactive oxygen species (ROS) using laser light at a wavelength of 1,267 nanometers, without using specific photosensitizers. This method, like the other Modulight photoimmunotherapy treatment modalities, is a minimally invasive and selective treatment strategy, aiming to improve the effectiveness and safety of glioma treatment.
Modulight's role in the GlioLighT project focuses on the development and optimization of advanced ultrashort pulse lasers, contributing its expertise to enhance the penetration of optical therapy through tissue. The project also explores the impact of laser therapy on immune cells, particularly macrophages, which play a crucial role in the body's response to tumor cells.
"We are happy to be part of this project," said Dr. Petteri Uusimaa, Founder and CTO of Modulight. "Our involvement in GlioLighT not only represents a significant advancement in our mission to contribute to global health through laser technology but also underscores our commitment to innovative research in the medical field. We look forward to the positive impact this project will have on glioma treatment and patient care."
The GlioLighT project is financed through the EIC Pathfinder program, a part of the European Union's Horizon Europe program.